| Literature DB >> 33169192 |
Qi Su1,2, Zhong-Xiang Xie2, Feng He2, Zhen-Chuan Liu2, Xiao-Jie Song2, Fu-Chun Zhao2, Dibin Li3, Feng-Yuan Che4.
Abstract
OBJECTIVE: Japanese encephalitis (JE) is a critical problem of public health worldwide; however, there is limited data about the clinical features and indicators of outcome in adults with severe Japanese encephalitis.Entities:
Keywords: Clinical manifestations; Japanese encephalitis; Linyi; Neurological features; Outcome
Year: 2020 PMID: 33169192 PMCID: PMC7652048 DOI: 10.1007/s10072-020-04867-8
Source DB: PubMed Journal: Neurol Sci ISSN: 1590-1874 Impact factor: 3.307
Demographic and clinical characteristics between the different groups of SJE.
| Clinical parameters | Average/total | Good prognosis group | Poor prognosis group | |
|---|---|---|---|---|
| 9 | 4 | 5 | ||
| Age (year, | 48.89 ± 15.33 | 45.75 ± 19.24 | 51.4 ± 13.2 | 0.616a |
| Admission time (day, | 4 ± 1.94 | 3.75 ± 2.22 | 4.2 ± 1.92 | 0.754a |
| Temperature (°C, | 39 ± 0.82 | 38.65 ± 0.94 | 39.46 ± 0.55 | 0.15a |
| GCS (score, | 5 (3, 10) | 10 (6, 12.5) | 3 (3, 7) | 0.056c |
| Headache (case (%)) | 6 (66.7) | 3 (75) | 3 (60) | 1b |
| Quadriplegia (case (%)) | 6 (66.7) | 3 (75) | 3 (60) | 1b |
| Coma (case (%)) | 6 (66.7) | 1 (25) | 5 (100) | |
| Status epilepticus (case (%)) | 4 (44.4) | 0 (0) | 4 (80) | |
| Increased muscle tone (case (%)) | 3 (33.3) | 1 (25) | 2 (40) | 1b |
| Meningeal stimulation sign (case (%)) | 7 (77.8) | 2 (50) | 5 (100) | 0.167b |
| Dyspnea (case (%)) | 7 (77.8) | 2 (50) | 5 (100) | 0.167b |
aStudent’s t test
bFisher’s exact test
cMann–Whitney U tests
Italicized text indicates p < 0.05
Hematology examination items of different groups of SJE
| Examination item | Good prognosis group | Poor prognosis group | Standard value | |
|---|---|---|---|---|
| 4 | 5 | |||
| Blood routine examination | ||||
| White blood cell (*109/L) | 6.52 ± 1.59 | 9.09 ± 4.48 | − 1.080 | 0.316a |
| Neutrophils (%) | 76 ± 1.9 | 85 ± 4.4 | − 3.84 | |
| Neutrophils (*109/L) | 4.95 ± 1.18 | 7.75 ± 3.93 | − 1.358 | 0.217a |
| Monocytes (%) | 8.5 ± 0.9 | 5.1 ± 3.0 | 2.366 | 0.066a |
| Monocytes (*109/L) | 0.56 ± 0.19 | 0.49 ± 0.35 | 0.362 | 0.728a |
| Lymphocyte (%) | 15.6 ± 1.7 | 8.9 ± 1.8 | 5.610 | |
| Lymphocyte (*109/L) | 1.01 ± 0.25 | 0.84 ± 0.32 | 0.846 | 0.425a |
| Blood biochemical examination | ||||
| AST (U/L) | 42.25 ± 48.37 | 45.90 ± 27.87 | − 0.143 | 0.89a |
| ALT (U/L) | 24.83 ± 25.12 | 38.18 ± 23.41 | − 0.824 | 0.437a |
| Creatinine (μmol/L) | 73.63 ± 17.87 | 57.22 ± 8.86 | 1.819 | 0.112a |
| Urea (mmol/L) | 4.49 ± 1.84 | 5.68 ± 3.15 | − 0.668 | 0.526a |
Italicized text indicates p < 0.05
aStudent’s 푡 test
MRI findings in brain and its composition ratio
| Parts | Total (%) | Good prognosis group ( | Poor prognosis group ( | |
|---|---|---|---|---|
| Multilesion (> 2) | 3 (42.9) | 2 (66.7) | 1 (25) | 0.486a |
| Thalamus | 6 (85.7) | 2 (66.7) | 4 (100) | 0.429a |
| Hippocampus | 5 (71.4) | 2 (66.7) | 3 (75) | 1a |
| Temporal lobe | 2 (28.6) | 1 (33.3) | 1 (25) | 1a |
| Midbrain | 2 (28.6) | 1 (33.3) | 1 (25) | 1a |
| Basal ganglia | 1 (14.3) | 0 (0) | 1 (25) | 1a |
| Insula | 1 (14.3) | 1 (33.3) | 0 (0) | 0.429a |
aFisher’s exact test
The sequela in 9 cases with SJE
| NO | Mental symptoms | Memory or comprehension disorders | Aphasias | Delayed response | Paralysis | Incontinence | MRS | |
|---|---|---|---|---|---|---|---|---|
| Dysphoria | Depressed | |||||||
| 1 | − | + | + | + | + | + | − | 5 |
| 2 | − | − | + | − | − | − | − | 1 |
| 3 | + | − | + | − | − | + | − | 4 |
| 4 | − | + | − | − | + | − | − | 2 |
| 5 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 6 |
| 6 | − | − | − | + | − | − | − | 1 |
| 7 | − | + | − | + | + | − | + | 3 |
| 8 | − | + | + | + | − | + | + | 5 |
| 9 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 6 |
| 5 (71.4%) | 4 (57.1%) | 4 (57.1%) | 3 (42.9%) | 3 (42.9%) | 2 (28.6%) | 4 (≥ 4) | ||
MRS scoring criteria: “0” no symptoms at all; “1” no significant sequelae despite symptoms, ability to perform all usual duties and activities; “2” mild sequelae, not able to complete all previously available activities, but able to handle personal matters without assistance; “3” moderate sequelae, daily life requires assistance, but walking does not; “4” severe sequelae, unable to walk without assistance from others and unable to fulfill their own physical needs; “5” extremely severe sequelae, bedridden, incontinent, requiring constant care and attention; “6” death
N/A, no data